Will Bed Bath & Beyond Ever Recover From COVID-19?

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Will Bed Bath & Beyond Ever Recover From COVID-19?

© jeepersmedia / Flickr

Bed Bath & Beyond Inc. (NASDAQ: BBBY) shares were crushed on Thursday after the company reported its most recent quarterly results. Analysts were calling for a net loss of $1.21 per share and $1.35 billion in revenue, but the posted net loss was $1.96 per share, on $1.31 billion in revenue. The same period of last year reportedly had $0.12 per share in earnings and $2.57 billion in revenue.

The company’s fiscal first quarter spanned the most critical months of the COVID-19 pandemic, which played into overall sales dropping by 49%. Much of this decline was due to temporary store closures and margin pressure from the substantial channel shift to digital.

Management noted that an important focus during the first quarter was to increase liquidity and optimize costs. The company had a fiscal 2019 year-end cash and investments balance of approximately $1.4 billion, and it ended the first quarter with $1.2 billion in cash and investments.

Prior to the end of the quarter, the company announced a new $850 million three-year secured asset-based revolving credit facility, which provides substantial additional liquidity if needed. It expires in June 2023 and replaces the company’s unsecured revolving credit facility that allowed for borrowings up to $250 million.

[nativounit]

The company declined to provide guidance due to the continued uncertainty of the ongoing pandemic. However, analysts are calling for a net loss of $0.43 per share and $2.21 billion in revenue for the second quarter.

Bed Bath & Beyond stock traded down about 22% to $8.11 on Thursday, in a 52-week range of $3.43 to $17.79. The consensus price target is $8.19.

[recirclink id=717691][wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618